Change over period
From:
To:
Zoom:
- 1Y
- 3Y
- 5Y
- 10Y
- 15Y
- 20Y
- Max
Leap Therapeutics Inc
NASDAQ LPTX
Data sourced from
and
and
Leap Therapeutics Inc Equity Multiplier 3 year CAGR for the quarter ending March 31, 2024: 0.83%
Leap Therapeutics Inc Equity Multiplier 3 year CAGR is 0.83% for the quarter ending March 31, 2024, a -97.48% change year over year. The Equity Multiplier measures the proportion of a company's assets that are financed by equity. It indicates the level of financial leverage in a company's capital structure. A higher ratio suggests a higher level of debt financing and indicates higher financial risk. The equity multiplier is useful in assessing the company's solvency and financial stability. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.
-
Leap Therapeutics Inc Equity Multiplier for the quarter ending March 31, 2023 was 3.76, a 250.02% change year over year.
-
Leap Therapeutics Inc Equity Multiplier for the quarter ending March 31, 2022 was 1.07, a -9.97% change year over year.
-
Leap Therapeutics Inc Equity Multiplier for the quarter ending March 31, 2021 was 1.19, a -25.40% change year over year.
-
Leap Therapeutics Inc Equity Multiplier for the quarter ending March 31, 2020 was 1.60, a -23.04% change year over year.
Don’t Miss A Beat
Looking to stay ahead of the competition and stay informed? Receive your daily dose of market news, trends, and analysis to kickstart your day and stay up-to-date.
NASDAQ: LPTX
| CEO | Mr. Douglas E. Onsi J.D. |
| IPO Date | Jan. 25, 2017 |
| Location | United States |
| Headquarters | 47 Thorndike Street, Cambridge, MA, United States, 02141 |
| Employees | 54 |
| Sector | Healthcare |
| Industry | Biotechnology |
Description
Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501. Leap Therapeutics, Inc. has an option and license agreement with NovaRock, Adimab, and BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.
Key trends
Similar companies
Day One Biopharmaceuticals Inc
NA
NA
Hepion Pharmaceuticals Inc
NA
NA
Acumen Pharmaceuticals Inc
NA
NA
StockViz Staff
September 20, 2024
Any question? Send us an email